About All G®

All G is an Australian biotechnology company developing high-value human and bovine milk proteins through precision fermentation.

Our journey

2021

Founded in Sydney; precision fermentation platform established

All G is founded in Sydney, Australia to build a precision fermentation platform for high-value, bioactive milk proteins.

Lab
2022

$45M raised; first product developed and pilot scale achieved

All G raises further institutional capital, taking total funding to approximately A$45 million. Partnership with Doehler provides a dedicated pilot facility in Germany to support scale-up.

Series A
2023

Core IP breakthrough; casein micelle technology established

All G files a patent showing that a stable casein micelle can be produced from a single casein protein type.

Scaling
2024

Scale up; commercial viability achieved; China CSAR approval

All G achieves commercially viable lactoferrin productivity and secures first round of regulatory approvals.

Scaling
2025

$10M strategic raise; JV formed with Savencia; Human milk IP filed

All G raies a further A$10 million in funding and forms a strategic joint venture with Armor Protéines (Savencia Group) to manufacture and commercialise human and bovine lactoferrin at global scale. All G files two new patents covering scalable casein micelle production and an infant formulation that includes all five major human breast milk proteins.

Scaling
2026

FDA GRAS ‘no questions'; commercial production begins

Commercial-scale production commences.

Scaling

Better beginnings start with better nutrition

Explore how our lactoferrin supports next-generation early life nutrition.

Our investors

All G’s mission is to deliver next-generation nutrition at global scale through precision fermentation, with a focus on high-value proteins including lactoferrin and broader human milk protein technologies. The company supports applications across infant formula, dietary supplements, and personal care, positioning All G within the next generation of global food and nutrition innovation.

All G contributes to sustainable protein production through precision fermentation, enabling scalable manufacture of high-purity proteins with consistent batch quality. This supports more controlled production, reduced variability, and reliable supply for high-value applications where infant formula-grade quality, safety, and performance are critical.

All G is headquartered in Zetland, Sydney, Australia, and operates across Asia-Pacific, China, Europe, and the United States. Its Sydney base supports access to Asia-Pacific markets while enabling global coordination, export, and engagement with international customers and partners.

All G is engaged with infant formula and personal care companies across Asia-Pacific, China, Europe, and the United States. These engagements support product development, validation, regulatory alignment, and commercialisation across multiple markets.

All G operates internationally and supports clients through ingredient supply, technical expertise, regulatory documentation, clinical trial data, and claims dossiers. This helps customers navigate approval, compliance, formulation, and commercialisation across infant formula, dietary supplement, and personal care applications.

All G works across key global markets including China, major European countries, and the United States, with expansion focused on regions that show strong demand for premium and functional proteins. China remains especially important given demand in premium and super premium categories and the role of both domestic channels and cross-border e-commerce.

All G differentiates through its ability to scale production of high-purity proteins while maintaining consistent infant formula-grade quality. The company has both bovine lactoferrin and human lactoferrin in development, alongside a broader pipeline of human milk proteins. Combined with strong intellectual property, regulatory capability, and commercial focus, this creates a differentiated platform for next-generation protein development.

All G’s leadership further strengthens this position. Chief Scientific Officer Jared Raynes led the world’s first development of recombinant human casein micelles, and CEO Jan Pacas has scaled and exited two technology companies. This combination of scientific depth and commercial execution sets All G apart in the global precision fermentation market.

All G primarily serves infant formula, dietary supplements, and personal care industries worldwide. Its focus is on high-value functional proteins for premium applications where purity, quality, consistency, and technical performance are critical.

All G’s team brings experience across biotechnology, food science, precision fermentation, and international regulatory systems. This includes expertise relevant to scale-up, product development, quality systems, and market entry across Asia-Pacific, China, Europe, and the United States.

Yes. All G is actively engaged with global infant formula, nutrition, and personal care companies to support ingredient development, validation, and future commercial supply across international markets.

All G aligns with international food safety, quality, and compliance frameworks to support global distribution and customer requirements. This includes structured quality systems, traceability, manufacturing controls, and documentation designed to meet the expectations of high-value food, nutrition, and personal care markets.

All G ensures consistent quality across regions through controlled precision fermentation processes, validated manufacturing systems, analytical verification, and strict quality control. The company’s focus on high-purity output and infant formula-grade quality standards supports batch consistency, traceability, and reliable performance across markets.

All G aligns with globally recognised frameworks including ISO 22000, FSSC 22000, HACCP, and GMP. These standards support food safety management, hazard control, traceability, manufacturing discipline, and quality consistency across global supply chains.